LGND LIGAND PHARMACEUTICALS INC Insider Trading

CLO Andrew Reardon sells 5,000 shares at blended avg $227.06 via scheduled 10b5-1 plan; retains 41,382 shares plus 39,444 option shares.

Andrew Reardon, CLO & Secretary, executed 7 separate sales totaling 5,000 shares for $1,135,315.57 on 2026-06-01 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-24, indicating this transaction was scheduled rather than discretionary. The insider retains 41,382 non-derivative shares post-sale, plus 39,444 shares in unexercised stock options, so the overall position remains materially intact. LGND's fundamentals show revenue growth of 60.4% year-over-year alongside a net loss of $13,345,000 in the latest quarter, suggesting the company is in a growth-but-not-yet-profitable phase. His prior 5 sales at LGND showed mixed near-term outcomes (30-day and 90-day returns ranging from -0.9% to +2.0%), offering no clear pattern of well-timed exits specific to this ticker. As a scheduled execution within his plan rather than a discretionary decision, this sale should not be interpreted as a timing call by the insider.

CLO Andrew Reardon sells 5,000 shares at $231.31 avg price via 10b5-1 plan; holds 41,382 shares post-sale

Andrew Reardon, CLO & Secretary, executed 7 separate sales totaling 5,000 shares for $1,156,555.60 on 2026-05-01 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-24. The current stock price of $218.98 is -11.5% from the 52-week high of $247.38 and -5.8% over the trailing 30 days, though +19.1% over 90 days. Reardon retains 41,382 shares post-transaction, representing a -10.8% reduction from his prior 46,382 share position. Because this sale is part of a scheduled 10b5-1 plan rather than a discretionary trade, the timing reflects a pre-established execution schedule rather than a current market or operational signal.